Sofosbuvir + Ledipasvir

Janessa M. Smith, PharmD, BCPS
Sofosbuvir + Ledipasvir is a topic covered in the Johns Hopkins ABX Guide.

To view the entire topic, please or .

Pediatrics Central™ is an all-in-one application that puts valuable medical information, via your mobile device or the web, in the hands of clinicians treating infants, children, and adolescents. Explore these free sample topics:

-- The first section of this topic is shown below --

INDICATIONS

FDA

  • Treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection.
    • Indicated for treatment of HCV infection in treatment-experienced patients without cirrhosis and with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C)
    • Treatment-naïve patients with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C), and liver transplant recipients.

-- To view the remaining sections of this topic, please or --

INDICATIONS

FDA

  • Treatment of chronic hepatitis C virus (HCV) genotype 1, 4, 5 or 6 infection.
    • Indicated for treatment of HCV infection in treatment-experienced patients without cirrhosis and with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C)
    • Treatment-naïve patients with compensated cirrhosis (Child-Pugh A) or decompensated cirrhosis (Child-Pugh B or C), and liver transplant recipients.

There's more to see -- the rest of this topic is available only to subscribers.

Last updated: July 31, 2016